During my career, I’ve been fortunate enough to work across both commissioning and provider roles.
On the commissioning side, I’ve led the development, procurement and commissioning of NHS neurodevelopmental and public health pathways. On the provider side, I’ve had to work within those systems, respond to commissioner decisions and manage the impact they have on services and patients.
That experience has changed how I look at Right to Choose. When you’re a provider, it’s natural to focus on the patients waiting for care, the capacity you have available and the service you’re ready to deliver. An Integrated Care Board (ICB) is looking at something much wider.
Understanding that wider picture doesn’t mean you have to agree with every decision an ICB makes. It does help you understand what is driving the decision, challenge it more effectively and put forward something the commissioner can actually act on.
What are ICBs considering when they make decisions?
One of the biggest differences between the provider and commissioner perspective is the scale of the picture they’re looking at.
A provider might be focused on one service, one pathway or one group of patients. An ICB has to consider that alongside demand elsewhere in the system, existing funded contracts, waiting lists, workforce pressures, quality, equality, available funding and the wider consequences of changing its approach.
That wider view can be difficult to see from the provider side and is likely to cause frustration. You might have patients waiting, available clinicians and a pathway that’s clinically ready to deliver. From your perspective, restricting activity can therefore feel hard to justify.
The commissioner may be looking at the same situation alongside a much bigger financial and operational picture.
The better you understand the pressures a commissioner is balancing, the easier it is to frame your response around what they can actually act on.
Why do ICBs restrict Right to Choose activity?
A common provider complaint is that ICBs are trying to stop activity or avoid paying independent providers.
I understand why it can feel that way, especially when Indicative Activity Plans (IAPs) arrive late, tariffs reduce and communication is unclear. Providers find themselves challenging decisions while already carrying responsibility for patients who are moving through their pathways.
Having seen it from the commissioning side, however, the underlying problem is often rapidly increasing or unplanned expenditure against budgets that are already under significant pressure.
That’s not to say every response to that pressure is fair or well managed. I remain critical where controls are introduced retrospectively without sufficient engagement, or where there hasn’t been enough consideration of patients already accepted into care. Providers need transparent information early enough to manage those clinical commitments safely.
Understanding the commissioner’s pressure doesn’t remove your right to challenge a decision. It helps you challenge it more effectively. That might mean asking for the evidence behind an activity decision, requesting a formal discussion, setting out the effect on patients already in the Right to Choose pathway and proposing a safe way forward.
Frame issues in a way commissioners can act on
My commissioning background has changed the way I frame problems. Saying an Indicative Activity Plan is too low may be completely justified, but on its own it doesn’t give the commissioner much to work with. A more useful response shows:
- Actual and forecast activity
- Patients already accepted and where they are in the pathway
- Clinical risk and priority
- Quality or equality implications
- The full cost of care
- The relevant contractual mechanism
- A workable alternative
The aim is to make the issue easy for someone inside the ICB to understand, evidence and take through their own decision-making process.
I cannot understate the importance of good documentation, too. Commissioning, contracting, finance and clinical leadership may sit with different people, and teams can change. Verbal assurance given in one meeting may never reach the person who ultimately needs to approve or act on it, which is why I’d always recommend putting the key evidence, decision and proposed solution clearly in writing.

Don’t just bring a provider problem to the table
The single, key piece of advice I’d give providers is this: bring the commissioner a solution as well as the problem.
If you tell an ICB that its plan doesn’t work, it might agree with you – and still have no obvious route to change it. A stronger proposal explains what’s happening, explains the patient consequences, provides accurate data and discusses an alternative. That way, the commissioner has something concrete to work with.
Before you go into that conversation, be ready to answer:
- What exactly is the issue?
- Which patients are affected?
- What is the financial impact?
- Are there quality or equality risks?
- What are you proposing instead?
- How would the revised position be monitored?
The easier you make it for someone inside the ICB to understand and defend the proposal internally, the more useful the conversation becomes.
How much do processes vary between ICBs?
One thing that surprised me when working across the market was just how much variation exists between ICBs, including in areas providers might reasonably expect to be more standardised.
Approaches can differ around accreditation, tariffs, Indicative Activity Plans, prior approval, referral interfaces, prescribing, shared care, data submissions, invoice validation and supplier onboarding.
Internal capacity can vary too. Organisational change, staffing reductions or unclear ownership between contracting, finance and clinical teams can all affect how quickly providers get a response.
So a delay doesn’t always mean an issue is being ignored. Sometimes the challenge is simply finding the right person with the authority to move it forward.
For providers, the important lesson is not to assume that a process which worked in one ICB will transfer unchanged to another. So keep clear records of local requirements, contacts, decisions and outstanding actions for each commissioning relationship.
Build a commissioner-ready evidence pack before you need one
Don’t wait until there’s an activity dispute, payment problem or urgent commissioner request to create an evidence pack. Do it now, and keep it current. In fact, it should form part of routine contract and commissioner relationship management.
Your pack might include:
- The qualifying contract and relevant service specification
- Current tariffs and what the pathway includes
- Patient numbers by ICB and pathway stage
- Waiting times and clinical priorities
- Forecast activity and cost
- Prescribing and shared-care arrangements
- Quality, outcomes and assurance information
- Data-reporting compliance
- Key contacts and a clear correspondence log
Keep reporting schedules current too, along with a running record of ICB-specific requirements, emails, meetings and decisions. Commissioners need this kind of evidence to make, amend and defend decisions internally.
If you can provide accurate, current information quickly, you’re more likely to have a productive conversation and less likely to be caught out by a late request or an activity plan that doesn’t reflect your current position.
Understanding both sides will make you a stronger provider
Right to Choose can create valuable capacity for providers and improve access for patients. It also sits within an NHS market where activity, funding and governance are increasingly closely managed.
You don’t need to accept every commissioner decision without question, but understanding the pressures, processes and governance behind those decisions gives you a much stronger basis from which to challenge them.
The most productive relationships are built when providers can combine high-quality patient care with clear evidence, strong contract management and a realistic understanding of what commissioners themselves need to manage.

Michelle Snook is a healthcare operations, commissioning and transformation specialist with experience across NHS and independent sector services. She has led the development, procurement, commissioning and delivery of neurodevelopmental and substance misuse pathways, with expertise spanning ADHD and autism services, contract management, governance and operational delivery.
Michelle is a Managing Partner at Regulum, where she advises on healthcare commissioning, provider strategy, pathway design and NHS market engagement. Having worked as both a commissioner and provider, she brings a practical understanding of how to build clinically robust, financially sustainable services that can navigate complex NHS commissioning requirements, including Right to Choose.

